Serina Therapeutics, Inc.
$2.10 +$0.03 (+1.45%) 1D Pre-marketKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
A material event was filed (Form 8-K).
8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 23
An insider transaction hit the record.
Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.
RECEIPT: SEC FORM 4, TIMESTAMPED -
Jul 22
A material event was filed (Form 8-K).
8-K - Serina Therapeutics, Inc. (0001708599) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Mar 25
The stock moved +24.7% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 25 -
Mar 19
The stock moved +93.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 19 -
Mar 18
From its Jan 30 high, the share price fell 61%.
Peak close $3.25 on Jan 30; trough close $1.28 on Mar 18. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -61%
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Serina Therapeutics, Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.